Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21401674 | 0.90 | LPL (0.42) | LPLLIPGF11CA1CA2 | |
| SCHEMBL12984904 | 0.86 | LPL (0.37) | LPLLIPGF11ESR2USP2 | |
| SCHEMBL14862313 | 0.84 | LPL (0.42) | LPLLIPGF11CA1CA2 | |
| SCHEMBL21876617 | 0.84 | LPL (0.39) | LPLLIPGF11CA1CA2 | |
| SCHEMBL2053569 | 0.83 | LIPG (0.41) | LPLLIPGF11CA1CA2 | |
| SCHEMBL20639989 | 0.83 | ESR2 (0.38) | LPLLIPGF11CA1CA2 | |
| SCHEMBL24681610 | 0.82 | LPL (0.46) | LPLLIPGF11CA1CA2 | |
| SCHEMBL9946218 | 0.82 | USP2 (0.46) | LPLLIPGF11CA1CA2 | |
| SCHEMBL20644417 | 0.82 | ESR2 (0.41) | LPLLIPGF11CA1CA2 | |
| SCHEMBL24495239 | 0.82 | LPL (0.47) | LPLLIPGF11ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | LPL 1450/4885LIPG 2704/4885F11 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.